BioPharmSignal logoBioPharmSignal

Biotech News

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Oculis (OCS)OculisClinical readout

Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention in diabetic macular edema (DME) management Oculis is on track to report topline results in June 2026 from DIAMOND Phase 3 registrational trials with OCS-01, which aims to be

Related news

OCSOculis2026-05-29 19:06 EST

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

OCSOculis2026-04-20 08:00 EST

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

EYPTEyePoint Pharmaceuticals2026-07-30 11:00 EST

EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)

MGTXMeiraGTx2026-04-14 12:30 EST

MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026

BLTEBelite Bio2026-07-20 12:00 EST

Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1

EYPTEyePoint Pharmaceuticals2026-05-14 11:00 EST

EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data

OCGNOcugen2026-03-24 11:45 EST

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

MGTXMeiraGTx2026-04-16 11:00 EST

MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia

PRQRProQR Therapeutics2026-06-25 10:25 EST

ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform

OCULOcular Therapeutix2026-04-13 11:00 EST

Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD

View all latest news

Oculis

Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective...

Recent company news

OCSOculis2026-08-06 20:05 EST

Oculis Reports Q2 2026 Financial Results and Provides Company Update

OCSOculis2026-08-03 08:00 EST

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

OCSOculis2026-07-08 20:05 EST

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

OCSOculis2026-07-02 08:00 EST

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

OCSOculis2026-07-02 08:00 EST

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

Stock data

Close
12.38 USD
Market cap
742.17M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States